Association Between RAS/BRAF Mutations and Complete Response Following Total Neoadjuvant Therapy in Patients with Rectal Cancer: A Prospective Multicentered Study

• Published in: Annals of surgical oncology Vol. 31; no. 3; pp. 1681 - 1689
• Main Authors: Bedrikovetski, Sergei, Traeger, Luke, Fitzsimmons, Tracy, Price, Timothy J., Ruszkiewicz, Andrew R., Vather, Ryash, Sammour, Tarik
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.03.2024; Springer Nature B.V
• Subjects: Cancer; Cancer therapies; Colorectal Cancer; Medicine; Medicine & Public Health; Metastases; Mutation; Oncology; Patients; Rectum; Response rates; Surgery; Surgical Oncology; NRAS; Keywords; Rectal cancer; RAS; KRAS; BRAF; Total neoadjuvant therapy
• ISSN: 1068-9265; 1534-4681
• DOI: 10.1245/s10434-023-14722-7

Background The impact of RAS/BRAF mutation on primary response rates after total neoadjuvant therapy (TNT) in patients with advanced rectal cancer is unclear. The aim of this study was to assess complete response rates after TNT according to RAS/BRAF mutation status. Methods A prospective observational study was performed in patients with rectal cancer who underwent TNT with curative intent at three South Australian hospitals between 2019 and 2023. Patients were classified according to their mutation status: mutant RAS/BRAF (mutRAS) or wild-type RAS/BRAF (wtRAS). The primary endpoint was overall complete response (oCR) rate, defined as the proportion of patients who achieved clinical complete response (cCR) and/or pathological complete response (pCR). Results Of the 150 patients eligible for inclusion, 80 patients with RAS/BRAF status available were identified. Of these, 43 (53.8%) patients were classified as mutRAS and 37 (46.3%) patients as wtRAS. Patients with mutRAS had significantly lower cCR and oCR rates after TNT than patients with wtRAS (14% vs. 37.8%, p  = 0.014; 11.6% vs. 43.2%, p  = 0.001, respectively). There was no significant difference in pCR rate between the groups. Of the 80 rectal cancer patients tested, 35 (43.8%) had metastatic disease (M1). There was no significant difference in complete M1 response rates between the groups (17.6% vs. 38.9%, p  = 0.254). Conclusion RAS/BRAF mutations negatively impact primary tumor response rates after TNT in patients with advanced rectal cancer. Large-scale national studies are needed to determine whether RAS/BRAF status could be used to select optimal oncologic therapy in rectal cancer patients.